Content about HGS

April 25, 2012

GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

NEW YORK — GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

Reuters reported that GSK's $13-per-share, $2.6 billion offer for HGS would give the former full control of Benlysta (belimumab), the first new drug approved by the Food and Drug Administration for lupus in more than half a century. The two companies developed the drug together under a partnership, and the drug received approval in March 2011.

October 4, 2010

Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment...

ROCKVILLE, Md. Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment for hepatitis C following the Food and Drug Administration’s decision to decline its approval, HGS said Tuesday.

 

HGS said it received a complete response letter from the FDA concerning the drug Zalbin (albinterferon alfa-2b). The FDA delivers a complete response letter to indicate that it has finished reviewing an application, but questions remain that preclude final approval.

 

 

July 12, 2010

A developer of a new drug for treating lupus has entered a supply agreement with...